Patents by Inventor Merrill Birkner

Merrill Birkner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20150111211
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • Predicting response to a HER inhibitor
    Patent number: 8940302
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: January 27, 2015
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110246399
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche, Inc.
    Inventors: LUKAS C. AMLER, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • PREDICTING RESPONSE TO A HER INHIBITOR
    Publication number: 20110245103
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 6, 2011
    Applicants: Genentech, Inc., Hoffmann-La Roche. Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • Predicting response to a HER inhibitor
    Patent number: 7981418
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Grant
    Filed: March 1, 2008
    Date of Patent: July 19, 2011
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
  • Predicting response to a HER inhibitor
    Publication number: 20100008975
    Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.
    Type: Application
    Filed: March 1, 2008
    Publication date: January 14, 2010
    Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss